Abstract
Background: Previous studies have demonstrated an association between high body mass index (BMI) and acute myeloid leukemias (AML). However, the results remain controversial. Aims: The aim of our study was to assess the impact of BMI on the outcome in adult patients with newly diagnosed AML Methods: Our study enrolled 140 patients with AML diagnosed between 2015 and 2020. The data were collected from Oncology Center, Mansoura University (OCMU) electronic medical record (eMR). They are further classified according to BMI into patients with normal BMI (40 patients), overweight (42 patients) and obese patients (58 patients) Results: No significant association is found between BMI and laboratory studies including CBCs, LDH (95% confidence interval [CI], P=0.645) or blast percentages in bone marrow aspirates (95% CI, p=0.587). As regard Complete Remission (CR) rates after induction chemotherapy with 3 + 7 protocol (three days of anthracycline+ seven days of cytrabine), our study concluded that CR rates are higher in patients with normal BMI when compared to overweight and obese patients (95% CI, p=0.004). BMI does not significantly affect disease-free survival (DFS) (95% CI, p=0.408). However, Higher BMI is associated with decreased overall survival (OS) (95% CI, p=0.004). Summary/Conclusion: In the treatment of acute myeloid leukemia in adults, overweight and obesity were associated with decreased complete response rates. However, overweight and obesity dont have a significant impact on disease free survival. A larger, prospective randomized trial would be required to confirm these results.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call